Ann: Chief Executive Officer and Managing Director Appointment, page-48

Novogen has an ovarian cancer drug (developed by Novogen) that completes Phase 1 in 2018.

A proposed name change to Kazia Therapeutics reflects the new lead compound and the arrival of a highly-experienced management team, led by Dr James Garner.
We value Novogen at 8 cents per share base case and 26 cents per share optimistic case. Our target price of 17 cents per share sits at the midpoint of our valuation range. We see Novogen being re-rated by the progress into the clinic of GDC-0084.

Heres the thing
JG took Kazia from 8c to $1.90c

Well Sam
Im really happy with that
: He obviously has contacts here and the US.